Inker, Lesley A.

KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease

Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 8,530

Estimating glomerular filtration rate from serum creatinine and cystatin C

Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 4,102

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality

Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 988

A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease

Delgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., et al. (2022) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesClinical Laboratory Practices and Quality Control

Cited by 783

Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis

Tangri, N., Grams, M. E., Levey, A. S., Coresh, J., Appel, L. J., Astor, B. C., Chodick, G., Collins, A. J., Djurdjev, O., Elley, C. R., et al. (2016) · JAMA

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 737

GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

Levey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 620

Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency

Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 591

Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Matzke, G. R., Aronoff, G. R., Atkinson, A. J., Bennett, W. M., Decker, B. S., Eckardt, K.-U., Golper, T., Grabe, D. W., Kasiske, B., Keller, F., et al. (2011) · Kidney International

Antibiotics Pharmacokinetics and EfficacyChronic Kidney Disease and Diabetes

Cited by 462

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 397

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Coresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 338

National Kidney Foundation Laboratory Engagement Working Group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: practical guidance for clinical laboratories

Miller, W. G., Kaufman, H. W., Levey, A. S., Straseski, J. A., Wilhelms, K. W., Yu, H. Y. (., Klutts, J. S., Hilborne, L. H., Horowitz, G. L., Lieske, J., et al. (2022) · Clinical Chemistry

Chronic Kidney Disease and DiabetesClinical Laboratory Practices and Quality Control

Cited by 222

A metabolome-wide association study of kidney function and disease in the general population

Sekula, P., Goek, O.-N., Quaye, L., Barrios, C., Levey, A. S., Römisch-Margl, W., Menni, C., Yet, I., Gieger, C., Inker, L. A., et al. (2016) · Journal of the American Society of Nephrology

Metabolomics and Mass Spectrometry StudiesChronic Kidney Disease and Diabetes

Cited by 203

Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate

Qiao, Y., Shin, J.-I., Chen, T. K., Inker, L. A., Coresh, J., Alexander, G. C., Jackson, J. W., Chang, A. R., & Grams, M. E. (2020) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 199

Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project

Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., et al. (2017) · Journal of the American Heart Association

Potassium and Related DisordersRenin-Angiotensin System Studies

Cited by 181

Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals

Fan, L., Levey, A. S., Gudnason, V., Eiriksdottir, G., Andresdottir, M. B., Gudmundsdottir, H., Indridason, O. S., Palsson, R., Mitchell, G., & Inker, L. A. (2015) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 170

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F. E., Shahinfar, S., Tuttle, K. R., Donner, J.-A., Jha, V., Nangaku, M., et al. (2020) · Kidney International

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 125

In Search of a Better Equation — Performance and Equity in Estimates of Kidney Function

Diao, J. A., Inker, L. A., Levey, A. S., Tighiouart, H., Powe, N. R., & Manrai, A. K. (2021) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesRace, Genetics, and Society

Cited by 115

Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease

Vonesh, E., Tighiouart, H., Ying, J., Heerspink, H. L., Lewis, J., Staplin, N., Inker, L., & Greene, T. (2019) · Statistics in Medicine

Statistical Methods in Clinical TrialsStatistical Methods and Bayesian Inference

Cited by 78

Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

Lambers Heerspink, H. J., Weldegiorgis, M., Inker, L. A., Gansevoort, R., Parving, H.-H., Dwyer, J. P., Mondal, H., Coresh, J., Greene, T., Levey, A. S., et al. (2014) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 69

Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes

Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., et al. (2024) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 24

Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: a population-based study.

Lyu, B., Chang, A. R., Inker, L. A., Selvin, E., Grams, M. E., & Shin, J.-I. (2022) · The Lancet Regional Health - Americas

Pharmacology and Obesity TreatmentObesity, Physical Activity, Diet

Cited by 22

Titration and discontinuation of semaglutide for weight management in commercially insured US adults

Xu, Y., Carrero, J. J., Chang, A. R., Inker, L. A., Zhang, D., Mukhopadhyay, A., Blecker, S. B., Horwitz, L. I., Grams, M. E., & Shin, J. (2025) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 16

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12